Iron catalyzes the generation of reactive oxygen species (ROS) as part of the innate antimicrobial defense. During sepsis, the dysregulated systemic inflammatory response to infection, iron homeostasis becomes disrupted, generating an excess of ROS causing damage to tissues. This can be potentially suppressed using iron chelators that selectively bind iron to prevent its participation in ROS-related inflammatory reactions.
OBJECTIVE:
We hypothesize that administration of DIBI, a novel iron-chelator, attenuates the dysregulated systemic immune response and reduces tissue damage in experimental endotoxemia.
METHODS:
Five groups of animals (n = 5–10) were included in this study: control, untreated endotoxemia, and endotoxemia animals treated with either DIBI-A, MAHMP, or DIBI-B. Intravital microscopy was performed on the intestine of anesthesized mice to observe leukocyte endothelial interactions and evaluate the intestinal microcirculation.
RESULTS:
Treatment of endotoxemic mice with DIBI-B reduced the number of adhering leukocytes in submucosal collecting (V1) venules by 68%. DIBI-B, MAHMP, and DIBI-A were able to restore functional capillary density (FCD) in the intestinal muscle layer by 74%, 44%, and 11%, respectively.
CONCLUSIONS:
DIBI-B reduces leukocyte recruitment and improves FCD in experimental endotoxemia, outperforming other chelators tested. These findings suggest a potential role for DIBI-B as a candidate drug for sepsis treatment.
CassatJ.E. and SkaarE.P., Iron in Infection and Immunity, Cell Host Microbe13(5) (2013), 509–519.
2.
BoomerJ.S., GreenJ.M. and HotchkissR.S., The changing immune system in sepsis: Is individualized immuno-modulatory therapy the answer?Virulence5(1), 2013, 45–56.
3.
HellingH., StephanB. and PindurG., Coagulation and complement system in critically ill patients, Clin Hemorheol Microcirc61(2) (2015), 185–193.
4.
CrouserE.D., Therapeutic benefits of antioxidants during sepsis: Is protection against oxidant-mediated tissue damage only half the story?Crit Care Med32(2) (2004), 589–590.
5.
KalinowskiD.S. and RichardsonD.R., The evolution of iron chelators for the treatment of Iiron overload disease and cancer, Pharmacol Rev57(4) (2005), 547–583.
6.
DaleS.E., Doherty-KirbyA., LajoieG. and HeinrichsD.E., Role of siderophore biosynthesis in virulence of Staphylococcus aureus: Identification and characterization of genes involved in production of a siderophore, Infect Immun72(1) (2004), 29–37.
7.
IslamS., JaroschS., ZhouJ., ParquetM.D.C., ToguriJ.T. and ColpP., et al. Anti-inflammatory and anti-bacterial effects of iron chelation in experimental sepsis, J Surg Res200 (2015), 1–8.
8.
SantosM.A., MarquesS.M. and ChavesS., Hydroxypyridinones as “privileged” chelating structures for the design of medicinal drugs, Coord Chem Rev256(1) (2012), 240–259.
9.
ZhouT., MaY., KongX. and HiderR.C., Design of iron chelators with therapeutic application, Dalton Trans41(21) (2012), 6371–6389.
10.
BurkovskiyI., LehmannC., JiangC. and ZhouJ., Utilization of 3D printing for an intravital microscopy platform to study the intestinal microcirculation, J Microsc264(2) (2016), 224–226.
11.
PavlovicD., FrielingH., LauerK-SS., BacV.H., RichterJ., WendtM., et al. Thermostatic tissue platform for intravital microscopy: “the hanging drop” model, J Microsc224(Pt 2) (2006), 203–210.
12.
LehmannC., GötzF., SchusterL. and ZhouJ., Improved setup for intestinal intravital microscopy in mice - the “ floating table.”, 2013;(January):102–103.
13.
ChiuC.J., McArdleA.H., BrownR., ScottH.J. and GurdF.N., Intestinal mucosal lesion in low-flow states: I. A morphological, hemodynamic, and metabolic reappraisal, Arch Surg101(4) (1970), 478.
14.
ScaliaR., The microcirculation in adipose tissue inflammation, Rev Endocr Metab Disord14(1) (2013), 69–76.
15.
LangerH.F. and ChavakisT., Leukocyte-endothelial interactions in inflammation, J Cell Mol Med13(7) (2009), 1211–1220.
16.
HayashiS., TakamiyaR., YamaguchiT., MatsumotoK., TojoS.J., TamataniT., et al. Induction of Heme Oxygenase-1 Suppresses VenularLeukocyte Adhesion Elicited by Oxidative Stress, Circ Res85(8), 1999.
17.
VachharajaniT.J., WorkJ., IssekutzA.C. and GrangerD.N., Heme oxygenase modulates selectin expression in different regional vascular beds, Am J Physiol - Hear Circ Physiol278(5), 2000.
18.
McCurdyT.R., PatrickA.L., Eltringham-SmithL.J., BhaktaV., SheffieldW.P. and Fox-RobichaudA.E., Alpha-1 Acid Glycoprotein Reduces Hepatic Leukocyte Recruitment in Murine Models of Either Early Endotoxemia or Early Sepsis, Microcirculation21(1) (2014), 74–83.
19.
InceC., The microcirculation is the motor of sepsis, Crit Care9(Suppl 4) (2005), S13–9.
20.
JungC., JungF. and KelmM., The microcirculation in hypoxia: The center of the battlefield for oxygen, Clin Hemorheol Microcirc63(3) (2016), 169–172.
21.
SareliusI.H., KuebelJ.M., WangJ. and HuxleyV.H., Macromolecule permeability of in situ and excised rodent skeletal muscle arterioles and venules, Am J Physiol - Hear Circ Physiol290(1), 2005.
22.
WangQ. and DoerschukC.M., The Signaling Pathways Induced by Neutrophil-Endothelial Cell Adhesion, Antioxid Redox Signal4(1) (2002), 39–47.
23.
SmithC.W., Possible steps involved in the transition to stationary adhesion of rolling neutrophils: A brief review, Microcirculation7(6 Pt 1) (2000), 385–394.
24.
CusnirR., ImbertiC., HiderR., BlowerP. and MaM., Hydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68, Int J Mol Sci18(1) (2017), 116.
25.
DobbinP.S., HiderR.C., HallA.D., TaylorP.D., SarpongP. and PorterJ.B., et al. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: Orally active iron chelators with clinical potential, J Med Chem36(17) (1993), 2448–2458.
26.
HatcherH.C., SinghR.N., TortiF.M. and TortiS.V., Synthetic and natural iron chelators: Therapeutic potential and clinical use, Future Med Chem1(9) (2009), 1643–1670.
27.
LawsonM.K., ValkoM., CroninM.T.D. and JomováK., Chelators inIron and Copper Toxicity, Curr Pharmacol Reports (2016), 271–280.
28.
SheldonJ.R. and HeinrichsD.E., Recent developments in understanding the iron acquisition strategies of gram positive pathogens. Whitfield C, editor, FEMS Microbiol Rev39(4) (2015), 592–630.
29.
LesicB., FoulonJ. and CarnielE., Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica, Antimicrob Agents Chemother46(6) (2002), 1741–1745.
30.
Power CoombsM.R., GrantT., GreenshieldsA.L., ArsenaultD.J., HolbeinB.E. and HoskinD.W., Inhibitory effect of iron withdrawal by chelation on the growth of human and murine mammary carcinoma and fibrosarcoma cells, Exp Mol Pathol99(2) (2015), 262–270.
31.
HolbeinB.E. and De OrdunaR.M., Effect of trace iron levels and iron withdrawal by chelation on the growth of Candida albicans and Candida vini, FEMS Microbiol Lett307 (2010), 19–24.
32.
KontoghiorghesG.J., KolnagouA., SkiadaA. and PetrikkosG., The Role of Iron and Chelators on Infections in Iron Overload and Non Iron Loaded Conditions: Prospects for the Design of New Antimicrobial Therapies, Hemoglobin34(3) (2010), 227–239.
33.
BruhnK.W. and SpellbergB., Transferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections, Curr Opin Microbiol27 (2015), 27.
34.
NeufeldE.J., Update on Iron Chelators in Thalassemia, Hematology2010(1) (2010), 451–455.
